Discover how iXpressGenes is making headlines as a leader in transformative trauma care.
Dec 17, 2024
iXpressGenes Appoints John Schmitt as CEO, Announces Nationwide TAI Test Launch
iXG is proud to appoint co-founder John Schmitt as Chief Executive Officer (CEO) and announce the nationwide launch of its Trauma Autoimmune Indicator (TAI) test
iXpressGenes develops new high performing DNA polymerase for COVID-19 and other pathogen testing
Scientists at iXpressGenes, on the campus of HudsonAlpha Institute for Biotechnology, have engineered a new reagent, critical to pathogen detection testing.
iXpressGenes awarded a $1M DoD contract to develop novel antibiotics from extremophilic microbiomes
iXG has developed a rare environmental DNA library from extremophilic environmental samples, collected from hot springs, thermal vents, and permafrost.
